Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Neuropathology and Applied Neurobiology|August 25, 2015
Audit of practice in sudden unexpected death in epilepsy (SUDEP) post mortems and neuropathological findingsMaria Thom, Zuzanna Michalak, Gabriella Wright, et al.
Acta Neuropathologica Communications|June 5, 2016
Imaging Invasion: Micro-CT imaging of adamantinomatous craniopharyngioma highlights cell type specific spatial relationships of tissue invasionJohn R Apps, J Ciaran Hutchinson, Owen J Arthurs, et al.
Acta Neuropathologica|July 13, 2022
Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma developmentMarina Danilenko, Masood Zaka, Claire Keeling, et al.
Neuropathology and Applied Neurobiology|April 7, 2021
Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnosticsStephen Crosier, Debbie Hicks, Edward C Schwalbe, et al.
The Lancet. Child & Adolescent Health|November 23, 2020
Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort studyRebecca M Hill, Stacey Richardson, Edward C Schwalbe, et al.
Epilepsia Open|October 15, 2021
The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasiaAnderson Brito da Silva, Jane Pennifold, Ben Henley, et al.
Cell Reports|August 4, 2022
Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar developmentDaniel Williamson, Edward C Schwalbe, Debbie Hicks, et al.
The Lancet. Oncology|May 27, 2017
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort studyEdward C Schwalbe, Janet C Lindsey, Sirintra Nakjang, et al.
Neuro-Oncology|July 17, 2021
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapseStacey Richardson, Rebecca M Hill, Christopher Kui, et al.
Cancer Cell|December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseRebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.
Pageof 5